Amarin Faces Critical Risks Following Loss of Key Patent Protections

Pharmaceutical firm Amarin (AMRN) is navigating a challenging period as it faces significant business risks stemming from the loss of patent protection for its primary drug. The company's heavy reliance on a single product has left it vulnerable to increasing generic competition in the market. In response to these pressures, Amarin has initiated aggressive cost-cutting measures aimed at generating positive cash flow. Analysts note that the legal loss of patent exclusivity represents a fundamental threat to the company's long-term revenue stream. Consequently, investor sentiment remains cautious as the firm struggles to maintain its financial stability amidst a shifting competitive landscape.